Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (NCT06031688)
A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
🩺 Plain-English Summary (8th-Grade Level)
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Who can join: Review the eligibility criteria below.
Location: Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
Age range: 18 Minutes
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (266 Sites)
Showing the first 25 of 266 sites.
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland — Saraland, Alabama
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Anaheim — Anaheim, California
- Sutter Auburn Faith Hospital — Auburn, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente-Fontana — Fontana, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
- Kaiser Permanente South Bay — Harbor City, California
- Kaiser Permanente-Irvine — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- Kaiser Permanente West Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Memorial Medical Center — Modesto, California
- Kaiser Permanente-Ontario — Ontario, California
- Palo Alto Medical Foundation Health Care — Palo Alto, California
- Kaiser Permanente - Panorama City — Panorama City, California
- Eisenhower Medical Center — Rancho Mirage, California
📞 Contact the Study Coordinator
Phone: (251) 435-2273
Email: donna.goggins@infirmaryhealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Recurrent Lung Non-Small Cell Carcinoma
- Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) — Fairbanks, Alaska
- Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer — Houston, Texas
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer — Scottsdale, Arizona
- NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer — Houston, Texas
- Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study — Birmingham, Alabama
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer — Anchorage, Alaska
Explore by condition: All Recurrent Lung Non-Small Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.